HK1083866A1 - Hla-a24-restricted cancer antigen peptides hla-a24 - Google Patents

Hla-a24-restricted cancer antigen peptides hla-a24

Info

Publication number
HK1083866A1
HK1083866A1 HK06103769.7A HK06103769A HK1083866A1 HK 1083866 A1 HK1083866 A1 HK 1083866A1 HK 06103769 A HK06103769 A HK 06103769A HK 1083866 A1 HK1083866 A1 HK 1083866A1
Authority
HK
Hong Kong
Prior art keywords
hla
cancer antigen
antigen peptides
restricted cancer
peptides
Prior art date
Application number
HK06103769.7A
Other languages
English (en)
Inventor
Haruo Sugiyama
Masashi Gotoh
Hideo Takasu
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Dainippon Sumitomo Pharma Co
International Institue Of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co, International Institue Of Cancer Immunology Inc filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of HK1083866A1 publication Critical patent/HK1083866A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06103769.7A 2002-06-12 2006-03-24 Hla-a24-restricted cancer antigen peptides hla-a24 HK1083866A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002171518 2002-06-12
JP2002275572 2002-09-20
PCT/JP2003/007463 WO2003106682A1 (ja) 2002-06-12 2003-06-12 Ｈｌａ−ａ２４拘束性癌抗原ペプチド

Publications (1)

Publication Number Publication Date
HK1083866A1 true HK1083866A1 (en) 2006-07-14

Family

ID=29738372

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06103769.7A HK1083866A1 (en) 2002-06-12 2006-03-24 Hla-a24-restricted cancer antigen peptides hla-a24

Country Status (11)

Country Link
US (2) US7420034B2 (de)
EP (1) EP1536009B1 (de)
JP (1) JP4365784B2 (de)
KR (1) KR101050703B1 (de)
CN (2) CN100408683C (de)
AT (1) ATE466084T1 (de)
AU (1) AU2003242305A1 (de)
CA (1) CA2489227C (de)
DE (1) DE60332355D1 (de)
HK (1) HK1083866A1 (de)
WO (1) WO2003106682A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940264D1 (de) 1998-07-31 2009-02-26 Int Inst Cancer Immunology Inc Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
ES2298353T3 (es) * 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
WO2003028757A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
CN100408683C (zh) * 2002-06-12 2008-08-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
EP1550453B1 (de) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Präparat eines peptids eines krebs-antigens
CA2513701C (en) * 2003-01-15 2013-06-18 Haruo Sugiyama Dimerized peptide
CA2893995A1 (en) * 2003-06-27 2005-01-06 International Institute Of Cancer Immunology, Inc. Method of diagnosis of cancer
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
ES2341785T3 (es) * 2004-03-31 2010-06-28 International Institute Of Cancer Immunology, Inc. Peptidos antigenicos del cancer derivados de wt1.
CN100427502C (zh) * 2005-06-09 2008-10-22 南京大学 抗肿瘤寡肽及其制备方法和应用
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
CN101336249A (zh) 2005-11-30 2008-12-31 株式会社癌免疫研究所 新型肽化合物
CA2886615A1 (en) 2006-02-22 2007-08-30 International Institute Of Cancer Immunology, Inc. Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
EP3834836A1 (de) 2006-04-10 2021-06-16 Memorial Sloan Kettering Cancer Center Immunogene wt-1-peptide und verwendungen davon
EP2341142B8 (de) * 2006-12-28 2015-01-14 International Institute of Cancer Immunology, Inc. HLA-A*1101-beschränktes WT1-Peptid und pharmazeutische Zusammensetzung damit
AU2008220031B2 (en) 2007-02-27 2013-06-13 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
WO2008109030A2 (en) * 2007-03-02 2008-09-12 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
CN101668853B (zh) 2007-03-05 2013-07-31 株式会社癌免疫研究所 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用
TWI504407B (zh) 2007-12-05 2015-10-21 Int Inst Cancer Immunology Inc 癌疫苗組合物
EP2684568B1 (de) * 2009-01-08 2017-11-15 International Institute of Cancer Immunology, Inc. Neuartiges Krebsantigen EEF2
CN102596209A (zh) * 2009-08-17 2012-07-18 国立大学法人东京大学 含有短暂性存活ctl的医药品组合物
EA037547B1 (ru) 2010-10-05 2021-04-12 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Способ активации хелперных т-клеток
EP3447140A3 (de) 2011-06-28 2019-05-29 International Institute of Cancer Immunology, Inc. Rezeptorgen für peptid-krebs-antigenspezifische t-zellen
CA2855358C (en) * 2011-11-11 2021-03-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
WO2013106834A2 (en) 2012-01-13 2013-07-18 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US20150150975A1 (en) 2012-07-02 2015-06-04 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
US10815288B2 (en) 2012-09-12 2020-10-27 International Institute Of Cancer Immunology, Inc. Antigen-specific helper T-cell receptor genes
CN110195040A (zh) 2012-12-17 2019-09-03 大塚制药株式会社 辅助性t细胞的活化方法
LT2945647T (lt) * 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6512568B2 (ja) * 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
RU2697443C2 (ru) * 2013-02-05 2019-08-14 Нитто Денко Корпорейшн Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
CA2840941A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
KR102121638B1 (ko) 2013-03-29 2020-06-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Wt1 항원 펩티드 콘쥬게이트 백신
EP3199627B1 (de) * 2014-09-24 2021-04-07 Sapporo Medical University Tumorantigenpeptide
CA2974066A1 (en) 2014-12-25 2016-06-30 International Institute Of Cancer Immunology, Inc. Method for modifying t cell population
LT3377516T (lt) 2015-11-20 2022-09-26 Memorial Sloan Kettering Cancer Center Kompozicija vėžiui gydyti
DK3539974T5 (en) 2016-11-09 2024-05-27 Univ Osaka Method for modifying t cell population
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
CA3113212A1 (en) 2018-09-28 2020-04-02 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
MX2021003938A (es) * 2018-10-05 2021-08-11 Int Inst Cancer Immunology Inc Composicion para prevenir o tratar un tumor benigno.
TW202045528A (zh) 2019-02-28 2020-12-16 日商大日本住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
KR20230009426A (ko) 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
KR20240046880A (ko) 2021-08-12 2024-04-11 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암을 처치 또는 예방하기 위한 의약 조성물 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034235A (en) 1995-06-01 2000-03-07 Tadamitsu Kishimoto Growth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1)
US20030092656A1 (en) 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
DE69940264D1 (de) 1998-07-31 2009-02-26 Int Inst Cancer Immunology Inc Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
ES2298353T3 (es) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
WO2003028757A1 (fr) 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
CN100408683C (zh) * 2002-06-12 2008-08-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽

Also Published As

Publication number Publication date
JP4365784B2 (ja) 2009-11-18
CN101113163B (zh) 2010-10-06
JPWO2003106682A1 (ja) 2005-10-13
US7420034B2 (en) 2008-09-02
US20070082860A1 (en) 2007-04-12
EP1536009A1 (de) 2005-06-01
CN101113163A (zh) 2008-01-30
CA2489227C (en) 2012-03-13
CA2489227A1 (en) 2003-12-24
WO2003106682A1 (ja) 2003-12-24
US7666985B2 (en) 2010-02-23
CN1675362A (zh) 2005-09-28
DE60332355D1 (de) 2010-06-10
EP1536009B1 (de) 2010-04-28
EP1536009A4 (de) 2006-06-07
KR20050010913A (ko) 2005-01-28
CN100408683C (zh) 2008-08-06
ATE466084T1 (de) 2010-05-15
AU2003242305A1 (en) 2003-12-31
AU2003242305A8 (en) 2003-12-31
US20090099090A1 (en) 2009-04-16
KR101050703B1 (ko) 2011-07-20

Similar Documents

Publication Publication Date Title
HK1083866A1 (en) Hla-a24-restricted cancer antigen peptides hla-a24
WO2018033254A3 (en) Rna for cancer therapy
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
EP2228072A4 (de) Krebsimpfstoff-zusammensetzung
HK1112367A1 (en) Survivin peptide vaccine
HK1144305A1 (zh) 衍生自 的癌抗原肽
SG163583A1 (en) Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
DK1871391T3 (da) Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
NZ593474A (en) Compositions and methods for treatment of celiac disease
MXPA04001524A (es) 29-enoles de rapamicina.
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
MXPA04001982A (es) Factor ix modificado.
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2006010106A3 (en) Dna-based vaccination of retroviral-infected individuals undergoing treatment
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
DK1444261T3 (da) Immunogene ALK (anaplastisk lymfomakinase) peptider
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
CY1111320T1 (el) Cripto ειδικα αντισωματα

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190610